by Clinical Neuropsychologist | Saturday, June 22, 2024 | Dementia
Abstract INTRODUCTION The recent introduction of seed amplification assays (SAAs) detecting misfolded α-synuclein, a pathology-specific marker for Lewy body disease (LBD), has allowed the in vivo identification and phenotypic characterization of patients with...
by Clinical Neuropsychologist | Saturday, June 22, 2024 | Dementia
Abstract The under-representation of non-European cohorts in neurodegenerative disease genome-wide association studies (GWAS) hampers precision medicine efforts. Despite the inherent genetic and phenotypic diversity in these diseases, GWAS research consistently...
by Clinical Neuropsychologist | Saturday, June 22, 2024 | Dementia
Abstract INTRODUCTION We examined whether the aging suppressor KLOTHO gene’s functionally advantageous KL-VS variant (KL-VS heterozygosity [KL-VSHET]) confers resilience against deleterious effects of aging indexed by cerebrospinal fluid (CSF) biomarkers of...
by Clinical Neuropsychologist | Saturday, June 22, 2024 | Dementia
Abstract INTRODUCTION Bumetanide, a loop diuretic, was identified as a candidate drug for repurposing for Alzheimer’s disease (AD) based on its effects on transcriptomic apolipoprotein E signatures. Cross-sectional analyses of electronic health records suggest...
by Clinical Neuropsychologist | Friday, June 21, 2024 | Dementia
Abstract INTRODUCTION Estimating treatment effects as time savings in disease progression may be more easily interpretable than assessing the absolute difference or a percentage reduction. In this study, we investigate the statistical considerations of the existing...
